Ground Swell Capital’s Novavax NVAX Stock Holding History

Ground Swell Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,916	Closed	-$201K	–	167
2022 Q2	$201K	Buy	+3,916	New	+$203K	0.37%	88

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Ground Swell Capital's NVAX Position: Q3 2022 in Review

Ground Swell Capital sold out of Novavax (NVAX) in Q3 2022, closing a stake of 3,916 shares — an estimated $201K sold.

Ground Swell Capital first reported a position in NVAX in Q2 2022 and held it in 1 quarter. The position peaked at $201K in Q2 2022. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

Ground Swell Capital reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
Ground Swell Capital sold 3,916 Novavax shares in Q3 2022, an estimated $201K.
Ground Swell Capital first reported a position in Novavax in Q2 2022 and held it in 1 quarter.
Ground Swell Capital's Novavax position peaked at $201K in Q2 2022.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Ground Swell Capital's 13F filing for Q3 2022, filed 14 Nov 2022.